Cargando…

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins

Mostrar otras versiones (1)

Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyuho, Ginsberg, Henry N., Choi, Sung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353557/ https://www.ncbi.nlm.nih.gov/pubmed/35929170 http://dx.doi.org/10.4093/dmj.2022.0198

Ejemplares similares

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
por: Morofuji, Yoichi, et al.
Publicado: (2022)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Statins and the Brain: More than Lipid Lowering Agents?
por: Fracassi, Anna, et al.
Publicado: (2019)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Lipid-lowering therapy using statins in patients with cardiovascular risk in clinical practice in Thailand
por: Silaruks, Songkwan, et al.
Publicado: (2011)

Effect and safety of combination lipid‐lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events
por: Wang, Chunli, et al.
Publicado: (2018)

Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering
por: Joo, Seung-Jae
Publicado: (2012)

Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
por: Deanfield, John E., et al.
Publicado: (2010)

Therapeutic implications of statins beyond lipid lowering: In the perspective of their effects on the antigen presentation, T cells and NKT cells
por: Khan, Masood Alam
Publicado: (2021)

Pleiotropic and Lipid–lowering Effects of Statins in Hypertension
por: Kamberi, Lulzim Selim, et al.
Publicado: (2012)

Lipid-lowering drugs (statins) and peripheral neuropathy
por: Emad, Mohammadreza, et al.
Publicado: (2018)

Novel Uses for Lipid-Lowering Agents
por: May, Megan Brafford, et al.
Publicado: (2016)

Statins in cardiometabolic disease: what makes pitavastatin different?
por: Ginsberg, Henry
Publicado: (2013)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

Pleiotropic use of Statins as non-lipid-lowering drugs
por: Zhang, Qijia, et al.
Publicado: (2020)

Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders
por: Lohoff, Falk W
Publicado: (2018)

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses
por: Ginsberg, Henry N.
Publicado: (2011)

Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering: A Potential Pleiotropic Effect
por: Raggi, Paolo, et al.
Publicado: (2019)

Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
por: Chaiyasothi, Thanaputt, et al.
Publicado: (2019)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Use of Statins as Lipid Lowering Agent in Hypercholesterolemia in a Tertiary Care Hospital: A Descriptive Cross-sectional Study
por: Bhattarai, Ashish Kumar, et al.
Publicado: (2020)

Statin therapy and lipids-lowering supplements – safe and effective treatment of lipids disturbances in children
por: Grabarczyk, Małgorzata, et al.
Publicado: (2022)

Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients
por: Wenger, N. K., et al.
Publicado: (2010)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Discovery of 7,9-Disulfatetrahydroberberine as Novel Lipid-Lowering Agents
por: Li, Dong-Dong, et al.
Publicado: (2020)

Patient perceptions and use of non‐statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
por: Lowenstern, Angela, et al.
Publicado: (2021)

Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations
por: Barber, Mathew J., et al.
Publicado: (2010)

Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
por: Bosco, Giosiana, et al.
Publicado: (2023)

Beyond Statins: Emerging Evidence for HDL-Increasing Therapies and Diet in Treating Cardiovascular Disease
por: Farrer, Sterling
Publicado: (2018)

Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
por: Kohli-Lynch, Ciaran N., et al.
Publicado: (2022)

Editorial: Beyond Cardiovascular Disease: Challenging New Pathways in Lipid and Lipoprotein Metabolism
por: Passarelli, Marisa, et al.
Publicado: (2022)

Diet in Stroke: Beyond Antiplatelets and Statins
por: James, Joe
Publicado: (2019)

KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment
por: Ruiz-Iruela, Cristina, et al.
Publicado: (2018)

Statins Lower Lipid Synthesis But Promote Secretion of Cholesterol-Enriched Extracellular Vesicles and Particles
por: Chen, Yundi, et al.
Publicado: (2022)

Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs
por: Engebretsen, Ingrid, et al.
Publicado: (2022)

Beneficial Effects of Statins on Seizures Independent of Their Lipid-Lowering Effect: A Narrative Review
por: Amanlou, Arash, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_krqsoqp3vdemt2kb3nso3tojam